Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

CBT on Fatigue in Survivors of Hodgkin Lymphoma

27. april 2021 opdateret af: Anja Mehnert, University of Leipzig

Cognitive Behavioral Therapy (CBT) Web-based Intervention on Fatigue in Survivors of Hodgkin Lymphoma - a Pilot Study

Background: Cancer-related fatigue is one of the most common patient-reported impairments in survivors of Hodgkin lymphoma and is associated with adverse effects on psychological well-being and everyday life including family, work and social participation.

Methods: The investigators here present a bi-centric (Cologne and Leipzig) pilot-study for a web-based intervention (Cognitive Behavioral Therapy) on cancer-related fatigue. In detail, the investigators will conduct a non-randomized and non-controlled before-and-after study in a minimum of 20 survivors of Hodgkin lymphoma. Levels of fatigue and quality of life will be measured before the intervention (T0), post-intervention (T1) and at 3-months follow-up (T2).

Results: The investigators will provide information regarding the feasibility of the intervention (i.e., response rate, patient and therapist adherence, and patient satisfaction) and preliminary results on the efficacy of the program in reducing CRF and increasing levels of quality of life.

Aims: The results of this pilot-study will provide essential information to conduct a future randomized clinical trial to investigate the efficacy of this intervention in reducing cancer-related fatigue in survivors with Hodgkin lymphoma.

Studieoversigt

Detaljeret beskrivelse

Concrete Aims: The investigators aim to conduct a a feasibility study, e.g., a pilot study before a randomized controlled trial can be planned in detail. This initial pilot-study is intended to test out the standard operating procedures, evaluate the feasibility, acceptance and adherence to the study protocol as well as preliminary efficacy of the web-based intervention for survivors of Hodgkin lymphoma. In detail, this study contains all preparation for conducting a trial, i.e., the translation, the adaptation and evaluation of the cognitive-behavioral web-based intervention manual from the original Dutch Version, the adaptation and implementation of all necessary technical and research-administrative requirements to successfully conduct the web-based randomized controlled trial and the evidence-based training of all study therapists including the implementation of therapists supervision. The investigators further assess adherence of the patients and therapists, the response rate and the patient satisfaction. Furthermore, preliminary efficacy of the intervention will be tested assessing levels of fatigue and quality of life at each measurement point.

Study Design: The design of this pilot web-based intervention on treating fatigue will be a non-randomised prospective non-controlled before-and-after study, in which observations will be made only in a patient group that receives the intervention. No control group will be recruited. Assessments will be conducted on the three measurement points: before the therapy (T0), after the intervention (T1) and 3 months after the intervention (T2).

Intervention: The internet-based cognitive behavioral therapy on postcancer fatigue includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months. The intervention will be specifically tailored to the individual needs of each patient: The therapy model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with Hodgkin lymphoma and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed. The intervention will consist of a maximum of eight treatment modules: aside from the six modules addressing the fatigue maintaining factor there is a module on goal formulation and realization of goals.

Recruitment: the recruitment will be realized on the basis of two ongoing trials of the German Hodgkin study group (HD 16- HD18) where fatigue of the patients is measured continuously.

Duration: The duration for patients will be 9 months (6 months intervention, 3 month-follow-up assessment). The duration of the whole study will be 18 months.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

17

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Cologne, Tyskland
        • University Medical Center Cologne
    • Saxony
      • Leipzig, Saxony, Tyskland, 04103
        • University Medical Center Leipzig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • fluency in German language
  • able to access the internet and use and follow a web-based Cognitive Behavioral intervention
  • in complete remission after treatment for newly diagnosed HL without signs of relapse (no previous relapse)
  • clinically relevant fatigue symptoms enduring at least 12 months after end of treatment (QLQ-C30 FA-12 ≥ 30 over at least two time points within the previous assessments in the course of the GHSG-trials)
  • fatigue being related to HL and its treatment and interferes with usual functioning, i.e. fulfills the definition of CRF [1, 16].

Exclusion Criteria:

  • Major communication difficulties
  • severe cognitive impairment that would interfere with a patient's ability to give informed consent for research (indicated by the medical care team)
  • Karnofsky Performance Status scale score < 70 predicting an expected survival of less than 6 months
  • somatic co-morbidities that could explain the presence of severe fatigue (e.g. Chronic Obstructive Pulmonary Disease or heart failure) according to the hemato-oncologists examining the potential participant before inclusion for the study
  • history of relapsed or refractory HL
  • clinical symptoms which may indicate a relapse of HL
  • current depressive disorder and related psychotropic or psychological treatment
  • Currently receiving medical and/or psychological treatment for a psychiatric disorder, other than the use of an anti-depressant
  • current treatment aimed at fatigue
  • previous attempt to treat fatigue with behavioral psychological therapy
  • pregnant or breastfeeding women

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Cognitive Behavioral Therapy for Treating Fatigue
This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.

The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.

The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Svarprocent
Tidsramme: Vurderingsperioden for dette resultat vil være fra rekrutteringsstart til inklusion af sidste patient, hvilket vil være omkring 1 år.
Efterforskerne vil vurdere mængden af ​​kvalificerede patienter, som er villige til at deltage i undersøgelsen i forhold til antallet af patienter, der blev inviteret til at deltage.
Vurderingsperioden for dette resultat vil være fra rekrutteringsstart til inklusion af sidste patient, hvilket vil være omkring 1 år.
Patienttilslutning
Tidsramme: Under interventionsfasen for hver patient, som vil være omkring sjette måned.
Patienttilslutning vil blive vurderet via dokumentation af patientfrafald. I detaljer vil vi dokumentere, om patienter forlader undersøgelsen under behandlingen (og hvis ja, på hvilket stadium).
Under interventionsfasen for hver patient, som vil være omkring sjette måned.
Patienttilfredshed
Tidsramme: Vurderes kun én gang for hver patient, umiddelbart efter at patienten har gennemført interventionen.
Vurderet ved et spørgeskema (Working Alliance Inventory - kort formular revideret). Den samlede sumscore på tværs af de 12 elementer, vurderet på en fem-punkts Likert-skala, vil blive præsenteret (fra 12 til 60). Højere værdier giver større tilfredshed.
Vurderes kun én gang for hver patient, umiddelbart efter at patienten har gennemført interventionen.
Therapist adherence
Tidsramme: Assessed during the intervention phase for each patient, i.e., within about 6 six months.
Using information of the therapy protocols of each participant, it will be assessed if the treatment sessions were done according to the treatment protocol.
Assessed during the intervention phase for each patient, i.e., within about 6 six months.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Levels of fatigue 1
Tidsramme: Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Assessed by a questionnaire, the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Module Measuring Cancer-Related Fatigue (EORTC QLQ-FA12). The questionnaire assesses the level of cancer-related fatigue. The sum score across all 12 items, rated on a 4-point Likert scale, will be reported (total range: 12-48). Higher values indicate higher levels of fatigue (i.e., higher values indicate a worse outcome).
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Levels of fatigue 2
Tidsramme: Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Levels of fatigue will additionally assessed by a second questionnaire, the Checklist Individual Strength - Subscale Fatigue Severity. The scale assesses the level of cancer-related fatigue. The sum score across all 8 items, rated on a 7-point Likert scale, will be presented (total range: 8 - 56). Higher values indicate higher levels of fatigue (i.e., higher values indicate a worse outcome).
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Global quality of life
Tidsramme: Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
Global quality of Life will be assessed by the European Organisation for Research and Treatment of Cancer (EORTC), Quality of Life-questionnaire (EORTC QLQ-C30). Global quality of life is assessed in a 2-item subscale of the questionnaire, each rated on a 7-point-Likert scale (total range: 2-14). According to the questionnaire manual, however, the sum score of the two items will be linear-transformed to a 0-100 scale, with higher values indicating higher levels of quality of life (i.e., higher values indicate a better outcome).
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Anja Mehnert, Prof. Dr., University of Leipzig
  • Ledende efterforsker: Peter Borchmann, Prof. Dr., University of Cologne

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. august 2018

Primær færdiggørelse (Faktiske)

28. februar 2021

Studieafslutning (Faktiske)

15. marts 2021

Datoer for studieregistrering

Først indsendt

24. august 2018

Først indsendt, der opfyldte QC-kriterier

27. maj 2019

Først opslået (Faktiske)

30. maj 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. april 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. april 2021

Sidst verificeret

1. april 2021

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner